Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, with diabetes mellitus (DM) being one of the most significant risk factors contributing to its development and progression. Diabetic patients are known to have a two- to four-fold increased risk of developing CAD compared to non-diabetic individuals [1]. Furthermore, CAD in diabetic patients is often more diffuse, involves multiple vessels, and is associated with more complex lesion morphology, which poses significant challenges in management. Percutaneous coronary intervention (PCI) has become a widely used revascularization strategy for patients with CAD due to advancements in stent technology and pharmacotherapy. However, diabetic patients continue to experience poorer outcomes following PCI compared to non-diabetic individuals [2]. This disparity is attributed to several pathophysiological mechanisms, including endothelial dysfunction, chronic inflammation, platelet hyperreactivity, and impaired vascular healing [3]. One of the major complications following PCI in diabetic patients is in-stent restenosis, which occurs due to excessive neointimal hyperplasia. Despite the use of drug-eluting stents (DES), which significantly reduce restenosis rates compared to bare-metal stents, diabetic patients still have a higher incidence of restenosis [4]. Additionally, stent thrombosis remains a serious concern in this population, as diabetes is associated with a prothrombotic state characterized by increased platelet aggregation and coagulation activity [5]. Another important aspect is the increased risk of peri-procedural and post-procedural complications, including bleeding, contrast-induced nephropathy, and vascular access complications. Diabetic patients often have coexisting comorbidities such as hypertension, dyslipidemia, and chronic kidney disease, further increasing their risk profile [6]. Large clinical trials such as the FREEDOM trial have demonstrated that diabetic patients with multivessel disease may benefit more from coronary artery bypass grafting (CABG) compared to PCI in terms of long-term outcomes [7]. However, PCI remains a preferred option in many cases due to its less invasive nature and shorter recovery time. Given these considerations, it is crucial to understand the complication profile of PCI in diabetic patients to optimize treatment strategies and improve clinical outcomes. This study aims to evaluate the complications associated with coronary interventions in diabetic patients and assess their impact on short-term outcomes.

This prospective observational study was conducted at a tertiary care cardiac center over a period of one year. A total of 100 patients with a confirmed diagnosis of diabetes mellitus undergoing percutaneous coronary intervention (PCI) were included in the study. Diabetes was defined based on previous diagnosis, use of antidiabetic medications, or fasting blood glucose levels ≥126 mg/dL. Patients aged ≥18 years with angiographically confirmed coronary artery disease and indicated for PCI were included. Patients with cardiogenic shock, prior CABG, severe renal failure, or active infection were excluded. Baseline demographic data, clinical history, and risk factors were recorded. PCI was performed using standard techniques via radial or femoral access. Drug-eluting stents were used in all patients. Patients received dual antiplatelet therapy with aspirin and a P2Y12 inhibitor. Procedural success was defined as <20% residual stenosis with TIMI grade 3 flow.Patients were followed for 12 months. Primary outcomes included major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or repeat revascularization. Secondary outcomes included procedural complications such as restenosis, stent thrombosis, and bleeding. Statistical analysis was performed using SPSS software. Data were expressed as mean ± SD and percentages. A p-value <0.05 was considered statistically significant.

Table 1: Baseline Characteristics Parameter Value Mean age 60.2 ± 8.5 years Male (%) 68% Hypertension 62% Dyslipidemia 55% Smoking 40% The study population consisted predominantly of middle-aged males with multiple cardiovascular risk factors, highlighting the high-risk profile of diabetic patients. Table 2: Procedural Details Parameter Value Drug-eluting stents used 100% Multivessel disease 70% Procedural success rate 93% A high procedural success rate was achieved despite the complexity of lesions in diabetic patients. Table 3: Complications Complication Percentage Restenosis 12% Stent thrombosis 5% Bleeding 8% Contrast nephropathy 6% Restenosis was the most common complication, followed by bleeding and stent thrombosis, consistent with known diabetic risk patterns. Table 4: Clinical Outcomes (12 months) Outcome Percentage MACE 18% Mortality 4% Myocardial infarction 6% Repeat PCI 8% The relatively high incidence of MACE reflects the increased vulnerability of diabetic patients after PCI.

The present study demonstrates that diabetic patients undergoing percutaneous coronary intervention are at a significantly higher risk of complications compared to the general population. The procedural success rate of 93% observed in this study is comparable to contemporary PCI outcomes, reflecting advancements in interventional techniques and stent technology. However, the complication rates remain substantial, underscoring the unique challenges associated with diabetes. One of the key findings is the high incidence of restenosis (12%), which continues to be a major limitation of PCI in diabetic patients. This can be attributed to enhanced neointimal proliferation driven by chronic inflammation and metabolic dysregulation [8]. Although drug-eluting stents have significantly reduced restenosis rates, diabetic patients still exhibit higher rates compared to non-diabetics, as reported in previous studies [4]. Stent thrombosis, observed in 5% of patients in this study, is another critical concern. Diabetes is associated with increased platelet reactivity and impaired fibrinolysis, contributing to a prothrombotic state [5]. Adequate dual antiplatelet therapy and adherence to treatment protocols are essential to mitigate this risk. The incidence of major adverse cardiovascular events (MACE) was 18% at 12 months, which aligns with findings from other clinical studies involving diabetic populations [2]. The increased risk of myocardial infarction and repeat revascularization highlights the need for aggressive risk factor modification and optimal glycemic control. Bleeding complications and contrast-induced nephropathy were also notable in this study. Diabetic patients often have underlying renal impairment, making them more susceptible to contrast-related complications [6]. Careful selection of contrast volume and preventive strategies are therefore crucial.Comparative trials such as the FREEDOM study have shown that CABG may offer better long-term outcomes in diabetic patients with multivessel disease [7]. However, PCI remains a viable option, particularly in patients who are not suitable candidates for surgery. The findings of this study emphasize the importance of individualized treatment strategies in diabetic patients undergoing PCI. Use of advanced imaging techniques, newer-generation stents, and strict control of metabolic parameters may help improve outcomes. Limitations of the study include a relatively small sample size and short follow-up duration. Larger multicenter studies are required to validate these findings and provide more robust evidence.

Diabetic patients undergoing coronary interventions are at increased risk of complications, including restenosis, stent thrombosis, and MACE. While PCI is effective, outcomes remain inferior compared to non-diabetic populations. Optimized procedural strategies, strict glycemic control, and long-term follow-up are essential to improve clinical outcomes.

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234. 2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-2581. 3. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent. N Engl J Med. 2004;350(3):221-231. 4. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541-1547. 5. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation. 1997;95(6):1366-1369. 6. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44(7):1393-1399. 7. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-2384. 8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323. 9. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351. 10. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease. Eur Heart J. 2010;31(16):1957-1967. 11. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Outcomes with various revascularization strategies in patients with diabetes mellitus. Circulation. 2012;125(23):2873-2891. 12. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents. Lancet. 2015;385(9985):2373-2381. 13. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease. Eur Heart J. 2018;39(3):213-260. 14. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. Guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541-2619. 15. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus. Circulation. 2009;119(3):430-436.